Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 440.54% from the stock’s current price.

Separately, Benchmark restated a “speculative buy” rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Unicycive Therapeutics currently has an average rating of “Buy” and a consensus target price of $5.50.

Unicycive Therapeutics Price Performance

NASDAQ UNCY opened at $0.74 on Wednesday. The stock’s 50 day simple moving average is $0.65 and its 200-day simple moving average is $0.49. The company has a market cap of $76.81 million, a PE ratio of -0.76 and a beta of 2.30. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.82.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bleakley Financial Group LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth $33,000. Great Point Partners LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $3,491,000. Acuta Capital Partners LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $807,000. Walleye Capital LLC acquired a new stake in Unicycive Therapeutics during the third quarter worth about $2,040,000. Finally, XTX Topco Ltd purchased a new position in Unicycive Therapeutics during the third quarter worth about $29,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.